TNFSF4 and systemic sclerosis: Amlitelimab (anti-OX40L mAb) is currently being explored in CONQUEST (Platform Clinical Study for Conquering Scleroderma), a multicentre randomized controlled platform trial for SSc interstitial lung disease.